Hainan Zhonghe Pharmaceutical Co., Ltd, established in 1995, is the first high-tech enterprise specialized in development, production and marketing of peptide drugs in China. The manufacturing site is located in the south of China. All the plants were designed and constructed strictly in compliance with GMP requirements. All the production lines, including small volume parenteral solution, lyophilized powder for injection and oral solid dosage forms, are GMP certified. Some of them successfully passed GMP audit by PIC/S members. In 1997, HEXIN® Thymopentin for injection, the first peptide drug developed by Zhonghe, was approved and launched, which marked the beginning of peptide industry in China. Since then, diversified peptide products were launched in succession, covering many therapeutic areas such as immune system, antineoplastics, hepatopathy, digestive system, urinary system, gynaecology and obstetrics etc. With the goal of 'manufacturing the best peptide medicine for the patients', Zhonghe takes the product quality as the life of the enterprise. Due to globally advanced machinery and rigorous GMP management, there is no quality trouble since the establishment of the company. Superior quality made Zhonghe the foremost brand in the domestic field of synthetic peptide drugs.

Related Categories

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)